サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1370502

卵巣がん市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
卵巣がん市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年10月15日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

市場概要：

世界の卵巣がん市場規模は2022年に19億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて11.56%の成長率（CAGR）を示し、2028年までに37億米ドルに達すると予測しています。

卵巣がんは、デオキシリボ核酸（DNA）の変異原性変化によって、卵巣の異常細胞が増殖し始め、外側の組織内膜や卵管から制御不能に増殖する悪性腫瘍です。現在のところ、抗腫瘍剤、抗悪性腫瘍剤、PARP阻害剤、分裂阻害剤、VEGF/VEGFR阻害剤など、さまざまな診断薬や薬剤の助けを借りて治療することができます。これとは別に、卵巣がんの治療には、手術、化学療法、ホルモン療法、放射線療法、標的療法などがあり、がん細胞を死滅させ、徴候や全身状態の緩和をもたらします。これらの治療法は、腫瘍の広がり、個人の一般的な健康状態、卵巣がんの大きさや種類など、複数の要因を判断した上で、医療従事者によって実行されます。

卵巣がんの市場動向：

乳がん遺伝子1（BRCA1）またはBRCA2の遺伝子変異に起因する、上皮性卵巣がん、間質性卵巣がん、胚細胞性卵巣がんの有病率の増加、特に女性の老年人口の増加が、主に市場成長の原動力となっています。これに伴い、ベバシズマブ（アバスチン）やパゾパニブ（ヴォトリエント）のような効果的な治療薬に対するニーズの高まりが、もう一つの成長促進要因として作用しています。さらに、薬剤耐性を防ぎ治療効果を高めるためにヘルスケア分野で併用療法が広く採用されていることも、市場の成長を支えています。さらに、先発医薬品の特許切れが進行していることから、政府や製薬会社は新規の遺伝子組換え医薬品を発売するようになり、これが市場の成長を後押ししています。さらに、卵巣がんの症状、治療法、早期卵巣がん診断の利点について消費者を啓発するために非政府組織（NGO）が行っている広範な取り組みが、市場の成長を後押ししています。これとは別に、主要企業間の戦略的提携や、効率的な治療介入を生み出すための継続的な研究開発（R&D）活動が、市場に明るい展望をもたらしています。

本レポートで扱う主な質問

  • 世界の卵巣がん市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の卵巣がん市場に与えた影響は？
  • 主要な地域市場は？
  • タイプ別の市場内訳は？
  • 治療タイプ別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の卵巣がん市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 卵巣がんの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 上皮性卵巣がん
    • 市場動向
    • 市場予測
  • 胚細胞性卵巣がん
    • 市場動向
    • 市場予測
  • 間質細胞卵巣がん
    • 市場動向
    • 市場予測

第7章 市場内訳：治療タイプ別

  • 免疫療法
    • 市場動向
    • 市場予測
  • 化学療法
    • 市場動向
    • 市場予測
  • 標的療法
    • 市場動向
    • 市場予測
  • 外科手術
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 在宅ケア
    • 市場動向
    • 市場予測
  • スペシャリティセンター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2022
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2022
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players
目次
Product Code: SR112023A6407

Abstract

Market Overview:

The global ovarian cancer market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.56% during 2023-2028.

Ovarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals' general health, and the size and type of ovarian cancer.

Ovarian Cancer Market Trends:

The increasing prevalence of epithelial, stromal, and germ cell ovarian cancer, especially amongst the female geriatric population, due to the genetic mutation of breast cancer gene 1 (BRCA1) or BRCA2, is primarily driving the market growth. In line with this, the rising need for effective therapeutic drugs, such as bevacizumab (Avastin) and pazopanib (Votrient), is acting as another growth-inducing factor. Additionally, the widespread adoption of combination therapies in the healthcare sector to prevent drug resistance and increase treatment efficacy is supporting the market growth. Moreover, the ongoing patent expiration of branded medications has prompted governments and pharmaceutical companies to launch novel recombinant drugs, which, in turn, is propelling market growth. Furthermore, extensive initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers regarding the symptoms, treatments, and benefits of early ovarian cancer diagnosis are impelling the market growth. Apart from this, strategic collaborations amongst key players and continuous research and development (R&D) activities to produce efficient therapeutic interventions are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ovarian cancer market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

Epithelial Ovarian Cancer

Germ Cell Ovarian Cancer

Stromal Cell Ovarian Cancer

Breakup by Treatment Type:

Immunotherapy

Chemotherapy

Targeted Therapy

Surgery

Others

Breakup by End User:

Hospitals

Homecare

Speciality Centre

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global ovarian cancer market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ovarian cancer market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global ovarian cancer market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis